Anika Therapeutics Inc. | TalkMarkets

Latest Posts

The Week Ahead In Biotech: Pharma Earnings Pick Up Pace

Article By: Benzinga

Saturday, July 20, 2019 8:56 PM EDT

Biotech stocks had a relatively muted performance last week. Johnson & Johnson kickstarted the second-quarter reporting season for big pharma companies, beating forecasts and an upward adjustment to its full-year sales guidance.

In this article: BMY, DGX, EW, JNJ, MRK, ANIK, BIIB, CELG, BHVN

Read

4 Sell-Ranked Drug Stocks To Avoid Ahead Of Q2 Earnings

Article By: Arpita Dutt

Monday, July 17, 2017 11:35 AM EDT

Earnings season for the biotech and pharma sector kicks off this week with industry bellwether Johnson & Johnson reporting second quarter results tomorrow before the market opens.

In this article: VRX, FLXN, RXDX, ANIK Also: JNJ, NVS

Read

Anika Therapeutics Offers A Long-Term Growth Opportunity With Robust Pipeline

Article By: KKD Healthcare Analytics

Wednesday, July 5, 2017 10:43 AM EDT

Anika Therapeutics has relatively mild risk profile. The company has established products in the market while its drug candidates have high probability of receiving the FDA approval as well as of performing well in the market.

In this article: ANIK

Read

Is Economic Growth Slowing – Is This Bull Market About To End?

Article By: Robert Maltbie

Saturday, May 13, 2017 6:51 PM EDT

US economic growth was expected to improve in 2017 but the initial release of the first quarter GDP was less than stellar. And bond yields declined recently – is this a forewarning of a weaker economy and what are the impacts on the equity markets?